Zhejiang Hua Yuan Pharma Co., Ltd. romanized
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference 5d8b2dbe83
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/13 06:42.
Drug filings
28 acceptance records as first applicant, grouped into 21 source drug names. Source data as of 2026/11/13 06:42.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
Bisoprolol Fumarate and Amlodipine Besylate Tablets 2 records · Latest accepted 2026/04/03
Supplement · 1Generic · 1
Roxithromycin Tablets 2 records · Latest accepted 2026/04/02
Supplement · 1Generic · 1
Pemafibrate Tablets 1 records · Latest accepted 2025/12/23
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2504355 | Generic | 2025/12/23 | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | CDE ↗ |
Nebivolol Tablets 1 records · Latest accepted 2025/07/22
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHL2500131 | Generic | 2025/07/22 | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | CDE ↗ |
Ezetimibe and Atorvastatin Calcium Tablets(II) 1 records · Latest accepted 2025/07/02
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2502335 | Generic | 2025/07/02 | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | CDE ↗ |
Upadacitinib Sustained-release Tablets 1 records · Latest accepted 2025/01/23
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2500441 | Generic | 2025/01/23 | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | CDE ↗ |
Nicardipine Hydrochloride Injection 1 records · Latest accepted 2024/12/18
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2404394 | Generic | 2024/12/18 | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | CDE ↗ |
依折麦布阿托伐他汀钙片(I) · No verified English name 1 records · Latest accepted 2024/11/29
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2404111 | Generic | 2024/11/29 | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | CDE ↗ |
Doxofylline Tablets 2 records · Latest accepted 2024/11/02
Generic · 2
Potassium Phosphates Injection 1 records · Latest accepted 2024/06/01
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2450312 | Supplement | 2024/06/01 | Zhejiang Hua Yuan Pharma Co., Ltd. romanized; Zhejiang Sai Mo Pharmaceutical Co., Ltd. romanized | CDE ↗ |
心脑健片 · No verified English name 1 records · Latest accepted 2024/01/05
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2400027 | Supplement | 2024/01/05 | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | CDE ↗ |
心脑健胶囊 · No verified English name 1 records · Latest accepted 2024/01/05
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2400026 | Supplement | 2024/01/05 | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | CDE ↗ |
Thioctic Acid Tablets 2 records · Latest accepted 2024/01/03
Generic · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2400003 | Generic | 2024/01/03 | Zhejiang Hua Yuan Pharma Co., Ltd. romanized; Zhejiang Sai Mo Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| CYHS2400002 | Generic | 2024/01/03 | Zhejiang Hua Yuan Pharma Co., Ltd. romanized; Zhejiang Sai Mo Pharmaceutical Co., Ltd. romanized | CDE ↗ |
清热明目茶 · No verified English name 1 records · Latest accepted 2023/12/27
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2302632 | Supplement | 2023/12/27 | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | CDE ↗ |
Alendronate Sodium Tablets 1 records · Latest accepted 2023/08/25
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2302266 | Generic | 2023/08/25 | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | CDE ↗ |
Amlodipine Besylate and Atorvastatin Calcium Tablets 3 records · Latest accepted 2023/03/14
Generic · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2300787 | Generic | 2023/03/14 | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2300786 | Generic | 2023/03/14 | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2200627 | Generic | 2022/04/22 | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | CDE ↗ |
Hydrotalcite Chewable Tablets 1 records · Latest accepted 2022/07/22
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2250456 | Supplement | 2022/07/22 | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | CDE ↗ |
Levodopa and Benserazide Hydrochloride Tablets 1 records · Latest accepted 2022/04/19
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2200607 | Generic | 2022/04/19 | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | CDE ↗ |
Doxofylline Injection 1 records · Latest accepted 2021/11/24
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2102172 | Supplement | 2021/11/24 | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | CDE ↗ |
Omeprazole and Sodium Bicarbonate Capsules 2 records · Latest accepted 2021/08/12
Generic · 2
Carbocysteine Tablets 1 records · Latest accepted 2021/05/19
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2150607 | Supplement | 2021/05/19 | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | CDE ↗ |
Changes in the last 90 days
0 events from 2026/08/16 to 2026/11/13. CDE data as of 2026/11/13 06:42; NMPA data as of 2026/11/12 18:32.
This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
- No matching records were found in the currently loaded source data; coverage dates are listed below.
Under review
2 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/13 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Roxithromycin Tablets | CYHB2600662 | Supplement | 2026/04/02 | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | CDE ↗ |
| Pemafibrate Tablets | CYHS2504355 | Generic | 2025/12/23 | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | CDE ↗ |
Catalogue holder records
22 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/13 06:39. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | Approval number | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Upadacitinib Sustained-release Tablets | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | 国药准字H20264996 | 2026/06/30 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Nicardipine Hydrochloride Injection | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | 国药准字H20264360 | 2026/05/19 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| 依折麦布阿托伐他汀钙片(I) · No verified English name | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | 国药准字H20264319 | 2026/05/12 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Doxofylline Tablets | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | 国药准字H20263657 | 2026/03/17 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Doxofylline Tablets | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | 国药准字H20263658 | 2026/03/17 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Potassium Phosphates Injection | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | Zhejiang Sai Mo Pharmaceutical Co., Ltd. romanized | 国药准字H20258192 | 2025/09/10 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Bisoprolol Fumarate and Amlodipine Besylate Tablets | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | 国药准字H20255101 | 2025/08/19 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Thioctic Acid Tablets | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | Zhejiang Sai Mo Pharmaceutical Co., Ltd. romanized | 国药准字H20255092 | 2025/08/19 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Thioctic Acid Tablets | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | Zhejiang Sai Mo Pharmaceutical Co., Ltd. romanized | 国药准字H20255091 | 2025/08/19 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Alendronate Sodium Tablets | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | 国药准字H20249329 | 2024/11/15 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Roxithromycin Tablets | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | 国药准字H20244020 | 2024/06/18 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Amlodipine Besylate and Atorvastatin Calcium Tablets | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | 国药准字H20243255 | 2024/02/23 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Amlodipine Besylate and Atorvastatin Calcium Tablets | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | 国药准字H20243256 | 2024/02/23 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Amlodipine Besylate and Atorvastatin Calcium Tablets | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | 国药准字H20243262 | 2024/02/23 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Levodopa and Benserazide Hydrochloride Tablets | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | 国药准字H20234663 | 2023/12/19 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Hydrotalcite Chewable Tablets | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | 国药准字H20103300 | 2023/08/16 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Omeprazole and Sodium Bicarbonate Capsules | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | 国药准字H20233977 | 2023/08/01 | Not stated by source | CDE ↗ |
| 奥美拉唑碳酸氢钠胶囊(II) · No verified English name | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | 国药准字H20233978 | 2023/08/01 | Not stated by source | CDE ↗ |
| Carbocysteine Tablets | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | 国药准字H33021221 | 2022/11/21 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Doxofylline Injection | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | 国药准字H20227105 | 2022/08/18 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Metronidazole Tablets | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | 国药准字H33020202 | 2022/03/30 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Ezetimibe and Atorvastatin Calcium Tablets(II) | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | Zhejiang Hua Yuan Pharma Co., Ltd. romanized | 国药准字H20266075 | 2026/09/22 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
0 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/13 06:41.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | |||||
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
2 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/13 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Carbocysteine Tablets | CYHB2301080 | Supplement | 2023/05/17 | Jin Hua Pharmaceuticals Technology (Hu Zhou) Co., Ltd. romanized; Zhejiang Hua Yuan Pharma Co., Ltd. romanized | CDE ↗ |
| Escitalopram Oxalate Tablets | CYHB2200325 | Supplement | 2022/02/15 | Zhejiang Bai Dai Pharmaceuticals Technology Co., Ltd. romanized; Zhejiang Hua Yuan Pharma Co., Ltd. romanized | CDE ↗ |
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/13 06:42
- Chemical-drug catalogue
- Last successful update: 2026/11/13 06:39
- Full API register
- Last successful update: 2026/11/13 06:41
- NMPA drug delivery notices
- Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete
First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.